Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway

Xenia Lojewski, John F. Staropoli, Sunita Biswas-legrand, Alexandra M. Simas, Larissa Haliw, Martin K. Selig, Scott H. Coppel, Kendrick A. Goss, Anton Petcherski, Uma Chandrachud, Steven D. Sheridan, Diane Lucente, Katherine B. Sims, James F. Gusella, Dolan Sondhi, Ronald Crystal, Peter Reinhardt, Jared Sterneckert, Hans Schöler, Stephen J. Haggarty & 3 others Alexander Storch, Andreas Hermann, Susan L. Cotman

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Neuronal ceroid lipofuscinosis (NCL) comprises ̃13 genetically distinct lysosomal disorders primarily affecting the central nervous system. Here we report successful reprograming of patient fibroblasts into induced pluripotent stem cells (iPSCs) for the two most common NCL subtypes: classic late-infantile NCL, caused by TPP1(CLN2) mutation, and juvenile NCL, caused by CLN3 mutation. CLN2/TPP1- and CLN3-iPSCs displayed overlapping but distinct biochemical and morphological abnormalities within the endosomal-lysosomal system. In neuronal derivatives, further abnormalities were observed in mitochondria, Golgi and endoplasmic reticulum. While lysosomal storage was undetectable in iPSCs, progressive disease subtype-specific storage material was evident upon neural differentiation and was rescued by reintroducing the non-mutated NCL proteins. In proof-of-concept studies, we further documented differential effects of potential small molecule TPP1 activity inducers. Fenofibrate and gemfibrozil, previously reported to induce TPP1 activity in control cells, failed to increase TPP1 activity in patient iPSC-derived neural progenitor cells. Conversely, nonsense suppression by PTC124 resulted in both an increase of TPP1 activity and attenuation of neuropathology in patient iPSC-derived neural progenitor cells. This study therefore documents the high value of this powerful new set of tools for improved drug screening and for investigating early mechanisms driving NCL pathogenesis.

Original languageEnglish
Article numberddt596
Pages (from-to)2005-2022
Number of pages18
JournalHuman Molecular Genetics
Volume23
Issue number8
DOIs
Publication statusPublished - 1 Apr 2014
Externally publishedYes

Fingerprint

Neuronal Ceroid-Lipofuscinoses
Induced Pluripotent Stem Cells
Mutation
Stem Cells
Gemfibrozil
Fenofibrate
Preclinical Drug Evaluations
Endoplasmic Reticulum
Mitochondria
Central Nervous System
Fibroblasts

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Lojewski, X., Staropoli, J. F., Biswas-legrand, S., Simas, A. M., Haliw, L., Selig, M. K., ... Cotman, S. L. (2014). Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway. Human Molecular Genetics, 23(8), 2005-2022. [ddt596]. https://doi.org/10.1093/hmg/ddt596

Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway. / Lojewski, Xenia; Staropoli, John F.; Biswas-legrand, Sunita; Simas, Alexandra M.; Haliw, Larissa; Selig, Martin K.; Coppel, Scott H.; Goss, Kendrick A.; Petcherski, Anton; Chandrachud, Uma; Sheridan, Steven D.; Lucente, Diane; Sims, Katherine B.; Gusella, James F.; Sondhi, Dolan; Crystal, Ronald; Reinhardt, Peter; Sterneckert, Jared; Schöler, Hans; Haggarty, Stephen J.; Storch, Alexander; Hermann, Andreas; Cotman, Susan L.

In: Human Molecular Genetics, Vol. 23, No. 8, ddt596, 01.04.2014, p. 2005-2022.

Research output: Contribution to journalArticle

Lojewski, X, Staropoli, JF, Biswas-legrand, S, Simas, AM, Haliw, L, Selig, MK, Coppel, SH, Goss, KA, Petcherski, A, Chandrachud, U, Sheridan, SD, Lucente, D, Sims, KB, Gusella, JF, Sondhi, D, Crystal, R, Reinhardt, P, Sterneckert, J, Schöler, H, Haggarty, SJ, Storch, A, Hermann, A & Cotman, SL 2014, 'Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway', Human Molecular Genetics, vol. 23, no. 8, ddt596, pp. 2005-2022. https://doi.org/10.1093/hmg/ddt596
Lojewski, Xenia ; Staropoli, John F. ; Biswas-legrand, Sunita ; Simas, Alexandra M. ; Haliw, Larissa ; Selig, Martin K. ; Coppel, Scott H. ; Goss, Kendrick A. ; Petcherski, Anton ; Chandrachud, Uma ; Sheridan, Steven D. ; Lucente, Diane ; Sims, Katherine B. ; Gusella, James F. ; Sondhi, Dolan ; Crystal, Ronald ; Reinhardt, Peter ; Sterneckert, Jared ; Schöler, Hans ; Haggarty, Stephen J. ; Storch, Alexander ; Hermann, Andreas ; Cotman, Susan L. / Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway. In: Human Molecular Genetics. 2014 ; Vol. 23, No. 8. pp. 2005-2022.
@article{69b9c70d103a49da954c1f4444eff5e7,
title = "Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway",
abstract = "Neuronal ceroid lipofuscinosis (NCL) comprises ̃13 genetically distinct lysosomal disorders primarily affecting the central nervous system. Here we report successful reprograming of patient fibroblasts into induced pluripotent stem cells (iPSCs) for the two most common NCL subtypes: classic late-infantile NCL, caused by TPP1(CLN2) mutation, and juvenile NCL, caused by CLN3 mutation. CLN2/TPP1- and CLN3-iPSCs displayed overlapping but distinct biochemical and morphological abnormalities within the endosomal-lysosomal system. In neuronal derivatives, further abnormalities were observed in mitochondria, Golgi and endoplasmic reticulum. While lysosomal storage was undetectable in iPSCs, progressive disease subtype-specific storage material was evident upon neural differentiation and was rescued by reintroducing the non-mutated NCL proteins. In proof-of-concept studies, we further documented differential effects of potential small molecule TPP1 activity inducers. Fenofibrate and gemfibrozil, previously reported to induce TPP1 activity in control cells, failed to increase TPP1 activity in patient iPSC-derived neural progenitor cells. Conversely, nonsense suppression by PTC124 resulted in both an increase of TPP1 activity and attenuation of neuropathology in patient iPSC-derived neural progenitor cells. This study therefore documents the high value of this powerful new set of tools for improved drug screening and for investigating early mechanisms driving NCL pathogenesis.",
author = "Xenia Lojewski and Staropoli, {John F.} and Sunita Biswas-legrand and Simas, {Alexandra M.} and Larissa Haliw and Selig, {Martin K.} and Coppel, {Scott H.} and Goss, {Kendrick A.} and Anton Petcherski and Uma Chandrachud and Sheridan, {Steven D.} and Diane Lucente and Sims, {Katherine B.} and Gusella, {James F.} and Dolan Sondhi and Ronald Crystal and Peter Reinhardt and Jared Sterneckert and Hans Sch{\"o}ler and Haggarty, {Stephen J.} and Alexander Storch and Andreas Hermann and Cotman, {Susan L.}",
year = "2014",
month = "4",
day = "1",
doi = "10.1093/hmg/ddt596",
language = "English",
volume = "23",
pages = "2005--2022",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway

AU - Lojewski, Xenia

AU - Staropoli, John F.

AU - Biswas-legrand, Sunita

AU - Simas, Alexandra M.

AU - Haliw, Larissa

AU - Selig, Martin K.

AU - Coppel, Scott H.

AU - Goss, Kendrick A.

AU - Petcherski, Anton

AU - Chandrachud, Uma

AU - Sheridan, Steven D.

AU - Lucente, Diane

AU - Sims, Katherine B.

AU - Gusella, James F.

AU - Sondhi, Dolan

AU - Crystal, Ronald

AU - Reinhardt, Peter

AU - Sterneckert, Jared

AU - Schöler, Hans

AU - Haggarty, Stephen J.

AU - Storch, Alexander

AU - Hermann, Andreas

AU - Cotman, Susan L.

PY - 2014/4/1

Y1 - 2014/4/1

N2 - Neuronal ceroid lipofuscinosis (NCL) comprises ̃13 genetically distinct lysosomal disorders primarily affecting the central nervous system. Here we report successful reprograming of patient fibroblasts into induced pluripotent stem cells (iPSCs) for the two most common NCL subtypes: classic late-infantile NCL, caused by TPP1(CLN2) mutation, and juvenile NCL, caused by CLN3 mutation. CLN2/TPP1- and CLN3-iPSCs displayed overlapping but distinct biochemical and morphological abnormalities within the endosomal-lysosomal system. In neuronal derivatives, further abnormalities were observed in mitochondria, Golgi and endoplasmic reticulum. While lysosomal storage was undetectable in iPSCs, progressive disease subtype-specific storage material was evident upon neural differentiation and was rescued by reintroducing the non-mutated NCL proteins. In proof-of-concept studies, we further documented differential effects of potential small molecule TPP1 activity inducers. Fenofibrate and gemfibrozil, previously reported to induce TPP1 activity in control cells, failed to increase TPP1 activity in patient iPSC-derived neural progenitor cells. Conversely, nonsense suppression by PTC124 resulted in both an increase of TPP1 activity and attenuation of neuropathology in patient iPSC-derived neural progenitor cells. This study therefore documents the high value of this powerful new set of tools for improved drug screening and for investigating early mechanisms driving NCL pathogenesis.

AB - Neuronal ceroid lipofuscinosis (NCL) comprises ̃13 genetically distinct lysosomal disorders primarily affecting the central nervous system. Here we report successful reprograming of patient fibroblasts into induced pluripotent stem cells (iPSCs) for the two most common NCL subtypes: classic late-infantile NCL, caused by TPP1(CLN2) mutation, and juvenile NCL, caused by CLN3 mutation. CLN2/TPP1- and CLN3-iPSCs displayed overlapping but distinct biochemical and morphological abnormalities within the endosomal-lysosomal system. In neuronal derivatives, further abnormalities were observed in mitochondria, Golgi and endoplasmic reticulum. While lysosomal storage was undetectable in iPSCs, progressive disease subtype-specific storage material was evident upon neural differentiation and was rescued by reintroducing the non-mutated NCL proteins. In proof-of-concept studies, we further documented differential effects of potential small molecule TPP1 activity inducers. Fenofibrate and gemfibrozil, previously reported to induce TPP1 activity in control cells, failed to increase TPP1 activity in patient iPSC-derived neural progenitor cells. Conversely, nonsense suppression by PTC124 resulted in both an increase of TPP1 activity and attenuation of neuropathology in patient iPSC-derived neural progenitor cells. This study therefore documents the high value of this powerful new set of tools for improved drug screening and for investigating early mechanisms driving NCL pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=84897873387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84897873387&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddt596

DO - 10.1093/hmg/ddt596

M3 - Article

VL - 23

SP - 2005

EP - 2022

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 8

M1 - ddt596

ER -